Selective modulation of the glucocorticoid receptor can distinguish between transrepression of NF-κB and AP-1

Cellular and Molecular Life Sciences

Volumn 71, Issue 1, 2014, Pages 143-163

  De Bosscher, Karolien ^a   Beck, Ilse M ^a,b   Dejager, Lien ^a,c   Bougarne, Nadia ^a   Gaigneaux, Anthoula ^d   Chateauvieux, Sébastien ^d   Ratman, Dariusz ^a   Bracke, Marc ^b   Tavernier, Jan ^a   Vanden Berghe, Wim ^a,e   Libert, Claude ^a,c   Diederich, Marc ^f   Haegeman, Guy ^a,g  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d LABORATOIRE DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE DU CANCER   (Luxembourg)

^e UNIVERSITY OF ANTWERP   (Belgium)

^f Seoul National University   (South Korea)

^g MAHIDOL UNIVERSITY   (Thailand)

Author keywords

c Jun; Glucocorticoids; Inflammation; Jun N terminal kinase (JNK); Mitogen activated protein kinase (MAPK); Selective GR modulator

Indexed keywords

COMPOUND A; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE TARGETING; GENETIC REGULATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; TOXICITY; TRANSACTIVATION; TRANSCRIPTION REGULATION; TRANSREPRESSION;

MUS;

EID: 84891883016     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-013-1367-4     Document Type: Article

References (68)

1. Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, Giguere V et al (2006) International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev 58:782-797 (Pubitemid 44833746)
2. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K et al (1995) The nuclear receptor superfamily: the second decade. Cell 83:835-839 (Pubitemid 26006525)
3. Wright AP, Zilliacus J, McEwan IJ, Dahlman Wright K, Almlof T, Carlstedt Duke J et al (1993) Structure and function of the glucocorticoid receptor. J Steroid Biochem Mol Biol 47:11-19 (Pubitemid 24040936)
4. So AY, Cooper SB, Feldman BJ, Manuchehri M, Yamamoto KR (2008) Conservation analysis predicts in vivo occupancy of glucocorticoid receptor-binding sequences at glucocorticoid-induced genes. Proc Natl Acad Sci USA 105:5745-5749 (Pubitemid 351758443)
5. Meijsing SH, Pufall MA, So AY, Bates DL, Chen L, Yamamoto KR (2009) DNA binding site sequence directs glucocorticoid receptor structure and activity. Science 324:407-410
6. Beck IM, Vanden Berghe W, Vermeulen L, Yamamoto KR, Haegeman G, De Bosscher K (2009) Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases. Endocr Rev 30:830-882
7. Rogatsky I, Wang JC, Derynck MK, Nonaka DF, Khodabakhsh DB, Haqq CM et al (2003) Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor. Proc Natl Acad Sci USA 100:13845-13850 (Pubitemid 37499154)
8. De Bosscher K, Haegeman G (2009) Minireview: latest perspectives on antiinflammatory actions of glucocorticoids. Mol Endocrinol 23:281-291
9. Vermeulen L, De Wilde G, Van Damme P, Vanden Berghe W, Haegeman G (2003) Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J 22:1313-1324 (Pubitemid 36362695)
10. Verstrepen L, Bekaert T, Chau TL, Tavernier J, Chariot A, Beyaert R (2008) TLR-4, IL-1R and TNF-R signaling to NF-kappaB: variations on a common theme. Cell Mol Life Sci 65:2964-2978
11. Bandyopadhyay RS, Faller DV (1997) Regulation of c-jun gene expression in endothelial cells by the protein kinase inhibitor staurosporine. Endothelium 5:95-105 (Pubitemid 27273678)
12. Vanden Berghe W, De Bosscher K, Boone E, Plaisance S, Haegeman G (1999) The nuclear factor-kappaB engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter. J Biol Chem 274:32091-32098 (Pubitemid 29522947)
13. Wagner EF (2010) Bone development and inflammatory disease is regulated by AP-1 (Fos/Jun). Ann Rheum Dis 69(Suppl 1):i86-i88
14. Vogt PK (2002) Fortuitous convergences: the beginnings of JUN. Nat Rev Cancer 2:465-469 (Pubitemid 37328943)
15. Wei P, Inamdar N, Vedeckis WV (1998) Transrepression of c-jun gene expression by the glucocorticoid receptor requires both AP-1 sites in the c-jun promoter. Mol Endocrinol 12:1322-1333 (Pubitemid 128496194)
16. Hazzalin CA, Mahadevan LC (2002) MAPK-regulated transcription: a continuously variable gene switch? Nat Rev Mol Cell Biol 3:30-40 (Pubitemid 135709916)
17. Angel P, Hattori K, Smeal T, Karin M (1988) The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell 55:875-885
18. Stein B, Angel P, van Dam H, Ponta H, Herrlich P, van der Eb A et al (1992) Ultraviolet-radiation induced c-jun gene transcription: two AP-1 like binding sites mediate the response. Photochem Photobiol 55:409-415
19. Shaulian E (2010) AP-1-The Jun proteins: oncogenes or tumor suppressors in disguise? Cell Signal 22:894-899
20. Yang-Yen HF, Chambard JC, Sun YL, Smeal T, Schmidt TJ, Drouin J et al (1990) Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 62:1205-1215 (Pubitemid 20333779)
21. Caelles C, Gonzalez-Sancho JM, Munoz A (1997) Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev 11:3351-3364 (Pubitemid 28023959)
22. Karin M (1995) The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 270:16483-16486
23. Bijlsma JW (2012) Disease control with glucocorticoid therapy in rheumatoid arthritis. Rheumatology (Oxford) 51 (Suppl 4):iv9-iv13
24. Schäcke H, Docke WD, Asadullah K (2002) Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96:23-43 (Pubitemid 35346616)
25. De Bosscher K (2010) Selective glucocorticoid receptor modulators. J Steroid Biochem Mol Biol 120:96-104
26. De Bosscher K, Haegeman G, Elewaut D (2010) Targeting inflammation using selective glucocorticoid receptor modulators. Curr Opin Pharmacol 10:497-504
27. Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R et al (1998) DNA binding of the glucocorticoid receptor is not essential for survival. Cell 93:531-541 (Pubitemid 28240715)
28. Tuckermann JP, Reichardt HM, Arribas R, Richter KH, Schütz G, Angel P (1999) The DNA binding-independent function of the glucocorticoid receptor mediates repression of AP-1-dependent genes in skin. J Cell Biol 147:1365-1370 (Pubitemid 30027391)
29. Belvisi MG, Wicks SL, Battram CH, Bottoms SE, Redford JE, Woodman P et al (2001) Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J Immunol 166:1975-1982 (Pubitemid 32114685)
30. Vandevyver S, Dejager L, Van Bogaert T, Kleyman A, Liu Y, Tuckermann J et al (2012) Glucocorticoid receptor dimerization induces MKP1 to protect against TNF-induced inflammation. J Clin Invest 122:2130-2140
31. Clark AR, Belvisi MG (2012) Maps and legends: the quest for dissociated ligands of the glucocorticoid receptor. Pharmacol Ther 134:54-67
32. Jewell CM, Scoltock AB, Hamel BL, Yudt MR, Cidlowski JA (2012) Complex human glucocorticoid receptor dim mutations define glucocorticoid-induced apoptotic resistance in bone cells. Mol Endocrinol 26:244-256
33. Vanden Berghe W, Plaisance S, Boone E, De Bosscher K, Schmitz ML, Fiers W et al (1998) p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. J Biol Chem 273:3285-3290 (Pubitemid 28109741)
34. De Bosscher K, Schmitz ML, Vanden Berghe W, Plaisance S, Fiers W, Haegeman G (1997) Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation. Proc Natl Acad Sci USA 94:13504-13509 (Pubitemid 28009612)
35. De Bosscher K, Vanden Berghe W, Beck IM, Van Molle W, Hennuyer N, Hapgood J et al (2005) A fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci USA 102:15827-15832 (Pubitemid 41552827)
36. De Bosscher K, Vanden Berghe W, Haegeman G (2001) Glucocorticoid repression of AP-1 is not mediated by competition for nuclear coactivators. Mol Endocrinol 15:219-227 (Pubitemid 32128703)
37. Beck IM, Vanden Berghe W, Gerlo S, Bougarne N, Vermeulen L, De Bosscher K et al (2009) Glucocorticoids and mitogen- and stress-activated protein kinase 1 inhibitors: possible partners in the combat against inflammation. Biochem Pharmacol 77:1194-1205
38. Reber LL, Daubeuf F, Plantinga M, De Cauwer L, Gerlo S, Waelput W et al (2012) A dissociated glucocorticoid receptor modulator reduces airway hyperresponsiveness and inflammation in a mouse model of asthma. J Immunol 188:3478-3487
39. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A et al (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034
40. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S et al (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5:R80
41. Smyth G (2005) Limma: linear models for microarray data. In: Gentleman R et al (eds) Bioinformatics and computational solutions using R and Bioconductor:397-420
42. Team RD (2010) A language and environment for statistical computing. Foundation for Statistical Computing, Vienna
43. Carlson M hgug4112a.db: Agilent "Human genome, Whole" annotation data (chip hgug4112a)
44. Zambelli F, Pesole G, Pavesi G (2009) Pscan: finding over-represented transcription factor binding site motifs in sequences from co-regulated or co-expressed genes. Nucleic Acids Res 37:W247-W252
45. Stormo GD (2000) DNA binding sites: representation and discovery. Bioinformatics 16:16-23 (Pubitemid 30204197)
46. Wasserman WW, Sandelin A (2004) Applied bioinformatics for the identification of regulatory elements. Nat Rev Genet 5:276-287 (Pubitemid 38435623)
47. Beck IM, Vanden Berghe W, Vermeulen L, Bougarne N, Vander Cruyssen B, Haegeman G et al (2008) Altered subcellular distribution of MSK1 induced by glucocorticoids contributes to NF-kappaB inhibition. EMBO J 27:1682-1693
48. Van Snick J, Cayphas S, Vink A, Uyttenhove C, Coulie PG, Rubira MR et al (1986) Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. Proc Natl Acad Sci USA 83:9679-9683 (Pubitemid 17223420)
49. De Bosscher K, Vanden Berghe W, Haegeman G (2003) The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 24:488-522 (Pubitemid 37059110)
50. Deroo BJ, Archer TK (2001) Glucocorticoid receptor activation of the I kappa B alpha promoter within chromatin. Mol Biol Cell 12:3365-3374 (Pubitemid 33108471)
51. Clark AR, Martins JR, Tchen CR (2008) Role of dual specificity phosphatases in biological responses to glucocorticoids. J Biol Chem 283:25765-25769
52. Brouckaert P, Everaerdt B, Fiers W (1992) The glucocorticoid antagonist RU38486 mimics interleukin-1 in its sensitization to the lethal and interleukin-6-inducing properties of tumor necrosis factor. Eur J Immunol 22:981-986
53. Huang P, Chandra V, Rastinejad F (2010) Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. Annu Rev Physiol 72:247-272
54. Vayssière BM, Dupont S, Choquart A, Petit F, Garcia T, Marchandeau C et al (1997) Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol 11:1245-1255 (Pubitemid 28041332)
55. Vanden Berghe W, Francesconi E, De Bosscher K, Resche-Rigon M, Haegeman G (1999) Dissociated glucocorticoids with anti-inflammatory potential repress interleukin-6 gene expression by a nuclear factor-kappaB-dependent mechanism. Mol Pharmacol 56:797-806 (Pubitemid 29491183)
56. Dewint P, Gossye V, De Bosscher K, Vanden Berghe W, Van Beneden K, Deforce D et al (2008) A plant-derived ligand favoring monomeric glucocorticoid receptor conformation with impaired transactivation potential attenuates collagen-induced arthritis. J Immunol 180:2608-2615
57. Wüst S, Tischner D, John M, Tuckermann JP, Menzfeld C, Hanisch UK et al (2009) Therapeutic and adverse effects of a non-steroidal glucocorticoid receptor ligand in a mouse model of multiple sclerosis. PLoS ONE 4:e8202
58. Rauch A, Gossye V, Bracke D, Gevaert E, Jacques P, Van Beneden K et al (2011) An anti-inflammatory selective glucocorticoid receptor modulator preserves osteoblast differentiation. Faseb J 25:1323-1332
59. Reuter KC, Grunwitz CR, Kaminski BM, Steinhilber D, Radeke HH, Stein J (2012) Selective glucocorticoid receptor agonists for the treatment of inflammatory bowel disease: studies in mice with acute trinitrobenzene sulfonic acid colitis. J Pharmacol Exp Ther 341:68-80
60. Rauner M, Goettsch C, Stein N, Thiele S, Bornhaeuser M, De Bosscher K et al (2011) Dissociation of osteogenic and immunological effects by the selective glucocorticoid receptor agonist, Compound A, in human bone marrow stromal cells. Endocrinology 152:103-112
61. van Loo G, Sze M, Bougarne N, Praet J, Mc Guire C, Ullrich A et al (2010) Antiinflammatory properties of a plant-derived nonsteroidal, dissociated glucocorticoid receptor modulator in experimental autoimmune encephalomyelitis. Mol Endocrinol 24:310-322
62. Yemelyanov A, Czwornog J, Gera L, Joshi S, Chatterton RT Jr, Budunova I (2008) Novel steroid receptor phyto-modulator Compound A inhibits growth and survival of prostate cancer cells. Cancer Res 68:4763-4773
63. Gossye V, Elewaut D, Bougarne N, Bracke D, Van Calenbergh S, Haegeman G et al (2009) Differential mechanism of NF-kappaB inhibition by two glucocorticoid receptor modulators in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 60:3241-3250
64. Kassel O, Schneider S, Heilbock C, Litfin M, Gottlicher M, Herrlich P (2004) A nuclear isoform of the focal adhesion LIM-domain protein Trip6 integrates activating and repressing signals at AP-1- and NF-kappaB-regulated promoters. Genes Dev 18:2518-2528 (Pubitemid 39362894)
65. Rogatsky I, Zarember KA, Yamamoto KR (2001) Factor recruitment and TIF2/GRIP1 corepressor activity at a collagenase-3 response element that mediates regulation by phorbol esters and hormones. EMBO J 20:6071-6083 (Pubitemid 33049282)
66. Bladh LG, Lidén J, Dahlman-Wright K, Reimers M, Nilsson S, Okret S (2005) Identification of endogenous glucocorticoid repressed genes differentially regulated by a glucocorticoid receptor mutant able to separate between nuclear factor-kappaB and activator protein-1 repression. Mol Pharmacol 67:815-826 (Pubitemid 40365329)
67. Tao Y, Williams-Skipp C, Scheinman RI (2001) Mapping of glucocorticoid receptor DNA binding domain surfaces contributing to transrepression of NF-kappa B and induction of apoptosis. J Biol Chem 276:2329-2332
68. Heck S, Kullmann M, Gast A, Ponta H, Rahmsdorf HJ, Herrlich P et al (1994) A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J 13:4087-4095 (Pubitemid 24275865)